A Phase 3 Open-Label Randomized Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma
Brief description of study
The purpose of this study involves research and is being conducted to determine the safety and efficacy of the investigational agent, rAd-IFN, when given with Celecoxib and Gemcitabine. The sponsor believes that rAd-IFN in combination with Celecoxib and Gemcitabine may help inhibit your tumor growth.
Clinical Study Identifier: s17-01785
ClinicalTrials.gov Identifier: NCT03710876
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
